Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuo, C.-C.
Right arrow Articles by Chang, J.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuo, C.-C.
Right arrow Articles by Chang, J.-Y.
[Cancer Research 64, 4621-4628, July 1, 2004]
© 2004 American Association for Cancer Research


Regular Articles

BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo

Ching-Chuan Kuo1, Hsing-Pang Hsieh2, Wen-Yu Pan1, Ching-Ping Chen2, Jing-Ping Liou2, Shiow-Ju Lee2, Yi-Ling Chang2, Li-Tzong Chen1, Chiung-Tong Chen2 and Jang-Yang Chang1

Divisions of 1 Cancer Research and 2 Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, Taiwan, ROC

BPR0L075 is a novel synthetic compound discovered through research to identify new microtubule inhibitors. BPR0L075 inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin. Cytotoxic activity of BPR0L075 in a variety of human tumor cell lines has been ascertained, with IC50 values in single-digit nanomolar ranges. As determined by flow cytometry, human cervical carcinoma KB cells are arrested in G2-M phases in a time-dependent manner before cell death occurs. Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicates that cell death proceeds through an apoptotic pathway. Additional studies indicate that the effect of BPR0L075 on cell cycle arrest is associated with an increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C. The changes in Cdc2 and Cdc25C coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. Furthermore, phosphorylated forms of Bcl-2, perturbed mitochondrial membrane potential, and activation of the caspase-3 cascade may be involved in BPR0L075-induced apoptosis. Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075. Moreover, BPR0L075 shows potent activity against the growth of xenograft tumors of the gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells at i.v. doses of 50 mg/kg in nude mice. These findings indicate BPR0L075 is a promising anticancer compound with antimitotic activity that has potential for management of various malignancies, particularly for patients with drug resistance.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
L.-C. Ma, C.-C. Kuo, J.-F. Liu, L.-T. Chen, and J.-Y. Chang
Transcriptional Repression of O6-Methylguanine DNA Methyltransferase Gene Rendering Cells Hypersensitive to N,N'-Bis(2-chloroethyl)-N-nitrosurea in Camptothecin-Resistant Cells
Mol. Pharmacol., August 1, 2008; 74(2): 517 - 526.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S.-F. Chang, C. A. Chang, D.-Y. Lee, P.-L. Lee, Y.-M. Yeh, C.-R. Yeh, C.-K. Cheng, S. Chien, and J.-J. Chiu
Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad
PNAS, March 11, 2008; 105(10): 3927 - 3932.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. H. Hwang, A. Rait, K. F. Pirollo, Q. Zhou, V. M. Yenugonda, G. M. Chinigo, M. L. Brown, and E. H. Chang
Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue
Mol. Cancer Ther., March 1, 2008; 7(3): 559 - 568.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-S. Kim, Y.-C. Lee, H.-T. Nam, G. Li, E.-J. Yun, K.-S. Song, K.-S. Seo, J.-H. Park, J.-W. Ahn, O. Zee, et al.
Apicularen A Induces Cell Death through Fas Ligand Up-Regulation and Microtubule Disruption by Tubulin Down-Regulation in HM7 Human Colon Cancer Cells
Clin. Cancer Res., November 1, 2007; 13(21): 6509 - 6517.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J.-P. Liou, K.-S. Hsu, C.-C. Kuo, C.-Y. Chang, and J.-Y. Chang
A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 398 - 405.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H.-T. Yao, Y.-S. Wu, Y.-W. Chang, H.-P. Hsieh, W.-C. Chen, S.-J. Lan, C.-T. Chen, Y.-S. Chao, L. Chang, H.-Y. Sun, et al.
Biotransformation of 6-Methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a Novel Antimicrotubule Agent, by Mouse, Rat, Dog, and Human Liver Microsomes
Drug Metab. Dispos., July 1, 2007; 35(7): 1042 - 1049.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S.-H. Juang, C.-C. Lung, P.-C. Hsu, K.-S. Hsu, Y.-C. Li, P.-C. Hong, H.-S. Shiah, C.-C. Kuo, C.-W. Huang, Y.-C. Wang, et al.
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation
Mol. Cancer Ther., January 1, 2007; 6(1): 193 - 202.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. L. Gururaja, D. Goff, T. Kinoshita, E. Goldstein, S. Yung, J. McLaughlin, E. Pali, J. Huang, R. Singh, S. Daniel-Issakani, et al.
R-253 disrupts microtubule networks in multiple tumor cell lines.
Clin. Cancer Res., June 15, 2006; 12(12): 3831 - 3842.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C.-C. Kuo, J.-F. Liu, and J.-Y. Chang
DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 946 - 954.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Hosono, T. Fukao, J. Ogihara, Y. Ito, H. Shiba, T. Seki, and T. Ariga
Diallyl Trisulfide Suppresses the Proliferation and Induces Apoptosis of Human Colon Cancer Cells through Oxidative Modification of {beta}-Tubulin
J. Biol. Chem., December 16, 2005; 280(50): 41487 - 41493.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Z. Chen, P. J. Merta, N.-H. Lin, S. K. Tahir, P. Kovar, H. L. Sham, and H. Zhang
A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth
Mol. Cancer Ther., April 1, 2005; 4(4): 562 - 568.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.